المؤلفون: Nomah, Daniel K, Reyes-Urueña, Juliana, Díaz, Yesika, Moreno, Sergio, Aceiton, Jordi, Bruguera, Andreu, Vivanco-Hidalgo, Rosa M, Llibre, Josep M, Domingo, Pere, Falcó, Vicenç, Imaz, Arkaitz, Cortés, Cristina, Force, Lluís, Letang, Emili, Vilaró, Ingrid, Casabona, Jordi, Miro, Jose M, Muntada, Esteve, Esteve, Anna, Riera, Melchor, Navarro, Gemma, Knobel, Hernando, Mallolas, Josep, Podzamczer, Daniel, Curran, Adrià, Burgos, Joaquín, Mateo, Maria Gracia, Gutierrez, Maria del Mar, Murillas, Javier, Homar, Francisco, Fernández-Montero, Jose Vicente, González, Eva, Peraire, Joaquim, Vidal, Francesc, Leon, Elena, Masabeu, Àngels, Orti, Amat-Joaquim, Dalmau, David, Jaen, Àngels, Deig, Elisabet, De Lazzari, Elisa, Berrocal, Leire, Fernandez, Guillem, Rodríguez, Lucía, Gargoulas, Freya, Vanrell, Toni, Rubia, Jose Carlos, Vilà, Josep, Martínez, Marina, Morell, Bibiana

المساهمون: Fundación La Caixa

المصدر: The Lancet HIV ; volume 8, issue 11, page e701-e710 ; ISSN 2352-3018

مصطلحات موضوعية: Virology, Infectious Diseases, Immunology, Epidemiology

الإتاحة: https://doi.org/10.1016/s2352-3018Test(21)00240-x
https://api.elsevier.com/content/article/PII:S235230182100240X?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S235230182100240X?httpAccept=text/plainTest

المؤلفون: Acin, Pablo, Luque, Sonia, Subirana, Isaac, Vila, Joan, Fernández-Sala, Xènia, Guelar, Ana, Antonio-Cuscó, Marta de, Arrieta, Itziar, Knobel, Hernando

المصدر: AIDS Research and Human Retroviruses ; volume 39, issue 10, page 533-540 ; ISSN 0889-2229 1931-8405

مصطلحات موضوعية: Infectious Diseases, Virology, Immunology

الإتاحة: https://doi.org/10.1089/aid.2022.0147Test

المؤلفون: Saumoy, Maria, Llibre, Josep M., Terrón, Alberto, Knobel, Hernando, Arribas, José Ramón, Domingo, Pere, Arroyo-Manzano, David, Rivero, Antonio, Moreno, Santiago, Podzamczer, Daniel

المصدر: AIDS Research and Human Retroviruses ; volume 33, issue 1, page 29-32 ; ISSN 0889-2229 1931-8405

مصطلحات موضوعية: Infectious Diseases, Virology, Immunology

الإتاحة: https://doi.org/10.1089/aid.2015.0386Test

المؤلفون: Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer, Daniel, Hontañón, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez-Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González-García, Juan, Berenguer, Juan, Imaz, Arkaitz, GESIDA-8314 Study Group

المساهمون: GESIDA-8314 Study Group, [Troya,J, Solís,J] Hospital Universitario Infanta Leonor, Madrid, Spain. [Ribera,E] Hospital Universitario Vall d’Hebrón, Barcelona, Spain. [Podzamczer,D, Imaz,A] ] Hospital Universitario de Bellvitge, Barcelona, Spain. [Hontañón,V, González-García,J] Hospital Universitario La Paz/IdiPAZ, Madrid, Spain. [Terrón,JA] Hospital Jerez de la Frontera, Jerez de la Frontera, Spain. [Boix,V] Hospital General Universitario de Alicante, Alicante, Spain. [Moreno,S] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Barrufet,P] Hospital de Mataró, Mataró, Spain. [Castaño,M, Berenguer,J] Hospital Regional Universitario de Málaga, Málaga, Spain. [Carrero,A] Hospital Universitario Gregorio Marañón, Madrid, Spain. [Galindo,MJ] Hospital Clínico de Valencia, Valencia, Spain. [Suárez-Lozano,I, Raffo,M] Hospital Universitario Infanta Elena, Huelva, Spain. [Knobel,H] Hospital del Mar, Barcelona, Spain. [Yllescas,M, Esteban,H] Fundación SEIMCGESIDA, Madrid, Spain., The study was supported by ViiV Healthcare and SEIMC-GESIDA Foundation (grant number Gesida-8314).

المصدر: PLoS ONE
PLoS ONE, Vol 11, Iss 10, p e0164455 (2016)
PLoS One
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Dipòsit Digital de la UB
Universidad de Barcelona
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-FISABIO. Repositorio Institucional de Producción Científica
Recercat. Dipósit de la Recerca de Catalunya
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

مصطلحات موضوعية: Male, HIV Infections, Pathology and Laboratory Medicine, Gastroenterology, Biochemistry, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Retrospective Studies [Medical Subject Headings], Immunodeficiency Viruses, Abacavir, Animal Cells, Análisis de intención de tratar, Lymphocytes, Masculino, lcsh:Science, Depression, Lamivudine, virus diseases, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Deoxycytidine::Zalcitabine::Lamivudine [Medical Subject Headings], Antiretrovirals, Lipids, Humanos, Drug Combinations, Cholesterol, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic::Intention to Treat Analysis [Medical Subject Headings], Medical Microbiology, Viral Pathogens, Lípidos, Drug Therapy, Combination, Cellular Types, medicine.medical_specialty, Immune Cells, 030106 microbiology, Immunology, Check Tags::Male [Medical Subject Headings], Chemicals and Drugs::Lipids [Medical Subject Headings], Microbiology, Limfòcits, Drug Administration Schedule, 03 medical and health sciences, Estudios retrospectivos, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA [Medical Subject Headings], VIH (Virus) -- Tractament, Humans, Microbial Pathogens, Retrospective Studies, Pharmacology, Blood Cells, lcsh:R, Rilpivirine, Organisms, Kidney metabolism, Recuento de Linfocito CD4, Abacavir/Lamivudine, Infecciones por Vih, Dideoxynucleosides, Regimen, chemistry, Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings], HIV-1, lcsh:Q, 0301 basic medicine, RNA viruses, lcsh:Medicine, Kidney, chemistry.chemical_compound, Efectos colaterales y reacciones adversas relacionados con medicamentos, White Blood Cells, Medicine and Health Sciences, Chemicals and Drugs::Pharmaceutical Preparations::Drug Combinations [Medical Subject Headings], Drug Interactions, 030212 general & internal medicine, Tasa de filtración glomerular, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Urological::Kidney Function Tests::Glomerular Filtration Rate [Medical Subject Headings], Multidisciplinary, Antimicrobials, Drugs, HIV diagnosis and management, Middle Aged, Antivirals, ARN, Treatment Outcome, Tolerability, Liver, Research Design, Viruses, RNA, Viral, Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings], Female, Estudios de seguimiento, Pathogens, VIH-1, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Deoxyribonucleosides::Dideoxynucleosides [Medical Subject Headings], medicine.drug, Research Article, Glomerular Filtration Rate, Adult, Efavirenz, Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings], Diseases::Chemically-Induced Disorders::Drug-Related Side Effects and Adverse Reactions [Medical Subject Headings], Clinical Research Design, Anti-HIV Agents, Phenomena and Processes::Cell Physiological Phenomena::Cell Count::Blood Cell Count::Leukocyte Count::Lymphocyte Count::CD4 Lymphocyte Count [Medical Subject Headings], Research and Analysis Methods, Internal medicine, Microbial Control, Virology, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings], Retroviruses, medicine, VIH (Virus), Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV::HIV-1 [Medical Subject Headings], Biology and life sciences, business.industry, HIV (Viruses), Lentivirus, HIV, Didesoxinucleósidos, Cell Biology, Antiretroviral agents, Diagnostic medicine, Surgery, CD4 Lymphocyte Count, Benzoxazinas, Adverse Events, Combinación de medicamentos, business

الوصف: OBJECTIVES: Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients. METHODS: We performed a multicenter, non-controlled, retrospective study of HIV-1-infected patients who switched treatment to ABC/3TC+RPV. Patients had an HIV-RNA

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb77d6c9cd4673b5095b0b326609743fTest
https://hdl.handle.net/10668/10526Test

المؤلفون: Bernardino, Jose I., Mocroft, Amanda, Wallet, Cedrick, de Wit, Stéphane, Katlama, Christine, Reiss, Peter, Mallon, Patrick W., Richert, Laura, Molina, Jean-Michel, Knobel, Hernando, Morlat, Philippe, Babiker, Abdel, Pozniac, Anton, Raffi, Francois, Arribas, Jose R., null, null

المصدر: PLoS ONE; 1/28/2019, Vol. 14 Issue 1, p1-13, 13p

مصطلحات موضوعية: ADIPOKINES, NUCLEOSIDES, NUCLEOTIDES, DARUNAVIR, TENOFOVIR

مستخلص: Background: Comparison of changes in body composition, adipokines and inflammatory markers after initial therapy with a nucleos(t)ide reverse transcriptase inhibitor (N(t)RTI)- sparing or containing regimen are scarce. Design: Randomised Clinical Trial. Methods: This is the body composition substudy of NEAT 001/ANRS 143, a randomised trial comparing darunavir/ritonavir (DRV/r) plus either raltegravir (RAL) or tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in 805 ART naïve HIV-infected adults. The primary endpoint was percentage change in limb fat at week 96. Secondary endpoints were associations among these changes and metabolic markers (IL-6, insulin, leptin, adiponectin, FGF-23). Results: 126 subjects (61 DRV/r + RAL and 65 DRV/r + TDF/FTC) were included. The rate of change in BMI between groups for RAL versus TDF/FTC at week 96 was 1.5% per 48-week period (p = 0.015). The rate of change in limb fat mass, trunk fat mass, total body fat and total lean mass was for RAL versus TDF/FTC at week 96 was 2.5% (p = 0.38), 7.3% ((p = 0.021), 4.9% (p = 0.061) and 1.3% (p = 0.12) respectively. Baseline insulin and leptin levels were correlated with baseline limb fat and trunk fat mass [r = 0.31 (p = 0.0043)/r = 0.28 (p = 0.0011) for limb fat, and r = 0.63 (p<0.0001)/r = 0.50(p<0.0001) for trunk fat]. After adjustment, a 10% faster increase in leptin between baseline and week 48 was associated with a more rapid increase in limb fat at week 48 (0.5% per 48 weeks, p<0.001), total body fat mass (0.6% per 48 weeks, p<0.001), and trunk fat mass (0.3% per 48 weeks, p = 0.0026). Conclusions: After week 96 a N(t)RTI sparing regimen of DRV/r + RAL produced a numerically greater percentage increase in body composition variables with only change in trunk fat mass and BMI being significant. [ABSTRACT FROM AUTHOR]

: Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Vallecillo, Gabriel, Domingo, Pere, Mallolas, Josep, Blanch, Jesús, Ferrer, Elena, Cervantes, Manuel, Pedrol, Enric, Knobel, Hernando, Llibre, Josep M.

المصدر: AIDS Research and Human Retroviruses ; volume 28, issue 2, page 165-170 ; ISSN 0889-2229 1931-8405

مصطلحات موضوعية: Infectious Diseases, Virology, Immunology

الإتاحة: https://doi.org/10.1089/aid.2011.0092Test

المؤلفون: Villar-García, Judit, Güerri-Fernández, Robert, Moya, Andrés, González, Alicia, Hernández, Juan J., Lerma, Elisabet, Guelar, Ana, Sorli, Luisa, Horcajada, Juan P., Artacho, Alejandro, D´Auria, Giuseppe, Knobel, Hernando

المصدر: PLoS ONE; 4/7/2017, Vol. 12 Issue 4, p1-15, 15p

مصطلحات موضوعية: GUT microbiome, IMMUNE response, ANTIRETROVIRAL agents, SACCHAROMYCES, RANDOMIZED controlled trials

مستخلص: Dysbalance in gut microbiota has been linked to increased microbial translocation, leading to chronic inflammation in HIV-patients, even under effective HAART. Moreover, microbial translocation is associated with insufficient reconstitution of CD4+T cells, and contributes to the pathogenesis of immunologic non-response. In a double-blind, randomised, placebo-controlled trial, we recently showed that, compared to placebo, 12 weeks treatment with probiotic Saccharomyces boulardii significantly reduced plasma levels of bacterial translocation (Lipopolysaccharide-binding protein or LBP) and systemic inflammation (IL-6) in 44 HIV virologically suppressed patients, half of whom (n = 22) had immunologic non-response to antiretroviral therapy (<270 CD4+Tcells/μL despite long-term suppressed viral load). The aim of the present study was to investigate if this beneficial effect of the probiotic Saccharomyces boulardii is due to modified gut microbiome composition, with a decrease of some species associated with higher systemic levels of microbial translocation and inflammation. In this study, we used 16S rDNA gene amplification and parallel sequencing to analyze the probiotic impact on the composition of the gut microbiome (faecal samples) in these 44 patients randomized to receive oral supplementation with probiotic or placebo for 12 weeks. Compared to the placebo group, in individuals treated with probiotic we observed lower concentrations of some gut species, such as those of the Clostridiaceae family, which were correlated with systemic levels of bacterial translocation and inflammation markers. In a sub-study of these patients, we observed significantly higher parameters of microbial translocation (LBP, soluble CD14) and systemic inflammation in immunologic non-responders than in immunologic responders, which was correlated with a relative abundance of specific gut bacterial groups (Lachnospiraceae genus and Proteobacteria). Thus, in this work, we propose a new therapeutic strategy using the probiotic yeast S. boulardii to modify gut microbiome composition. Identifying pro-inflammatory species in the gut microbiome could also be a useful new marker of poor immune response and a new therapeutic target. [ABSTRACT FROM AUTHOR]

: Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)